feeding frenzy, page-2

  1. 130 Posts.
    and here's the burley:
    During the Company’s most recent FDA review meeting, QRxPharma presented a position that although
    the Combination Rule does not require a demonstration of greater efficacy or safety, the data submitted to
    date indicate a safety advantage for MOXDUO compared to either morphine or oxycodone alone. Results
    from Study 022, which demonstrated that oxygen desaturation was less severe with MOXDUO than with
    oxycodone or morphine, were presented to the full review committee and noted with interest. The FDA
    recommended the Company provide a more extensive analysis of Study 022 when the revised MOXDUO
    New Drug Application (NDA) is resubmitted
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.